offline
Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug
Shares of Global Blood Therapeutics Inc. GBT, +49.18% shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, works by increasing the binding of oxygen to hemoglobin, the molecule that carries oxygen in red blood cells.
...
https://www.marketwatch.com/story/global...yptr=yahoo
![[Bild: GBTc1dl1415.png]](https://finviz.com/publish/120318/GBTc1dl1415.png)
Shares of Global Blood Therapeutics Inc. GBT, +49.18% shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, works by increasing the binding of oxygen to hemoglobin, the molecule that carries oxygen in red blood cells.
...
https://www.marketwatch.com/story/global...yptr=yahoo
